Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

2014/01/09 by Stéphane Palfi, Jean Marc Gurruchaga, G Scott Ralph +48 · 1 citation
Biochemistry, Genetics and Molecular Biology · Medicine · Neuroscience · #Nerve injury and regeneration #Neurological disorders and treatments #Virus-based gene therapy research

paper · doi:10.1016/s0140-6736(13)61939-x

openalex publication_date 2014/01/09 · crossref created 2014/01/09 · crossref issued 2014/03/01 · crossref published 2014/03/01 · crossref published-print 2014/03/01 · crossref deposited 2019/08/06 · openalex created_date 2025/10/10 · crossref indexed 2026/07/15 · openalex updated_date 2026/07/28

Citations

• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
• Tyrosine hydroxylase and regulation of dopamine synthesis

Cited by

• Lentiviral vector in gene therapy [wikipedia]